Burjeel Holdings reported a substantial 128.9% increase in second-quarter net profit to AED 148 million (US$40.3 million), driven by higher inpatient and outpatient volumes, improved patient yield, and the continued ramp-up of recently launched facilities. For the first half of 2025, net profit rose 10.6% to AED 187 million (US$50.9 million).
The second-quarter rebound followed a slowdown in March, which the company attributed to the Holy Month of Ramadan. Patient numbers recovered strongly, with inpatient volumes up 17.7% and outpatient volumes rising 12% during the quarter.
Quarterly revenue advanced 18.7% to AED 1,403 million (US$382 million), while half-year revenue increased 12.2% to AED 2,677 million (US$728.9 million). The group recorded 3.4 million patient visits and 22,930 surgeries, an 18.7% increase year-on-year. Bed occupancy improved to 69% from 65% in the prior year, and inpatient volumes for the first half grew by 14.6%.
Outpatient growth was supported by increased activity in primary care, physiotherapy, oncology, paediatrics, ophthalmology, and family medicine. Facility utilisation rose to 68% from 65% in the previous quarter.
Oncology remained a primary growth driver, with revenue rising 36.7% in the second quarter and 38.1% in the first half, supported by network expansion and stronger adoption of surgical and advanced therapies. Other specialities also delivered double-digit growth in the first half, including urology (18%), emergency medicine (17%), and cardiology (16%).
